Incyte Corporation vs SoundHound AI Inc — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while SoundHound AI Inc trades at $5.39 (market cap $2.45B). The key difference: Incyte Corporation is far larger — about 9.3× SoundHound AI Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and SoundHound AI Inc for 23 Days on average.
| INCY | SOUN | |
|---|---|---|
Market Cap | $22.85B | $2.45B |
Volume | 1,927,029 | 16,881,989 |
Sector | Health | Technology |
52-Week High | $129.93 | $21.40 |
52-Week Low | $83.80 | $5.39 |
Typical Hold Time | 33 Days | 23 Days |
Enterprise Value | $18.35B | $2.25B |
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
SoundHound AI (SOUN) trades at $5.52, down 1.95% amid bearish technical signals despite recent earnings beats. The company shows strong revenue growth with 2025 revenue of $168.92M and projected 2026 revenue of $203M, but faces significant profitability challenges with a -67.45% net income margin. Recent developments include expansion into banking AI agents and the OASYS Edge embedded architecture launch for vehicles and smart devices.
While analyst consensus remains bullish with a $9.33 price target (75% buy ratings), the stock faces headwinds from persistent losses, negative cash flow projections for 2026, and insider selling activity. The key investment thesis hinges on voice AI adoption growth versus the company's ability to achieve profitability amid high valuation multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →